| pubmed-article:15612023 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:15612023 | lifeskim:mentions | umls-concept:C0123931 | lld:lifeskim |
| pubmed-article:15612023 | lifeskim:mentions | umls-concept:C2931822 | lld:lifeskim |
| pubmed-article:15612023 | lifeskim:mentions | umls-concept:C0085405 | lld:lifeskim |
| pubmed-article:15612023 | lifeskim:mentions | umls-concept:C0282460 | lld:lifeskim |
| pubmed-article:15612023 | lifeskim:mentions | umls-concept:C0205179 | lld:lifeskim |
| pubmed-article:15612023 | lifeskim:mentions | umls-concept:C0701185 | lld:lifeskim |
| pubmed-article:15612023 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:15612023 | pubmed:dateCreated | 2005-2-1 | lld:pubmed |
| pubmed-article:15612023 | pubmed:abstractText | This Phase II study was designed to evaluate the efficacy and safety of irinotecan in patients with advanced nasopharyngeal carcinoma (NPC). | lld:pubmed |
| pubmed-article:15612023 | pubmed:language | eng | lld:pubmed |
| pubmed-article:15612023 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15612023 | pubmed:citationSubset | AIM | lld:pubmed |
| pubmed-article:15612023 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15612023 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15612023 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:15612023 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:15612023 | pubmed:month | Feb | lld:pubmed |
| pubmed-article:15612023 | pubmed:issn | 0008-543X | lld:pubmed |
| pubmed-article:15612023 | pubmed:author | pubmed-author:BalramChowbay... | lld:pubmed |
| pubmed-article:15612023 | pubmed:author | pubmed-author:LeongSwan-Swa... | lld:pubmed |
| pubmed-article:15612023 | pubmed:author | pubmed-author:TanEng-HuatEH | lld:pubmed |
| pubmed-article:15612023 | pubmed:author | pubmed-author:CheungYin-Bun... | lld:pubmed |
| pubmed-article:15612023 | pubmed:author | pubmed-author:PoonDonaldD | lld:pubmed |
| pubmed-article:15612023 | pubmed:copyrightInfo | (c) 2004 American Cancer Society | lld:pubmed |
| pubmed-article:15612023 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:15612023 | pubmed:day | 1 | lld:pubmed |
| pubmed-article:15612023 | pubmed:volume | 103 | lld:pubmed |
| pubmed-article:15612023 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:15612023 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:15612023 | pubmed:pagination | 576-81 | lld:pubmed |
| pubmed-article:15612023 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:15612023 | pubmed:meshHeading | pubmed-meshheading:15612023... | lld:pubmed |
| pubmed-article:15612023 | pubmed:meshHeading | pubmed-meshheading:15612023... | lld:pubmed |
| pubmed-article:15612023 | pubmed:meshHeading | pubmed-meshheading:15612023... | lld:pubmed |
| pubmed-article:15612023 | pubmed:meshHeading | pubmed-meshheading:15612023... | lld:pubmed |
| pubmed-article:15612023 | pubmed:meshHeading | pubmed-meshheading:15612023... | lld:pubmed |
| pubmed-article:15612023 | pubmed:meshHeading | pubmed-meshheading:15612023... | lld:pubmed |
| pubmed-article:15612023 | pubmed:meshHeading | pubmed-meshheading:15612023... | lld:pubmed |
| pubmed-article:15612023 | pubmed:meshHeading | pubmed-meshheading:15612023... | lld:pubmed |
| pubmed-article:15612023 | pubmed:meshHeading | pubmed-meshheading:15612023... | lld:pubmed |
| pubmed-article:15612023 | pubmed:meshHeading | pubmed-meshheading:15612023... | lld:pubmed |
| pubmed-article:15612023 | pubmed:meshHeading | pubmed-meshheading:15612023... | lld:pubmed |
| pubmed-article:15612023 | pubmed:meshHeading | pubmed-meshheading:15612023... | lld:pubmed |
| pubmed-article:15612023 | pubmed:meshHeading | pubmed-meshheading:15612023... | lld:pubmed |
| pubmed-article:15612023 | pubmed:meshHeading | pubmed-meshheading:15612023... | lld:pubmed |
| pubmed-article:15612023 | pubmed:meshHeading | pubmed-meshheading:15612023... | lld:pubmed |
| pubmed-article:15612023 | pubmed:meshHeading | pubmed-meshheading:15612023... | lld:pubmed |
| pubmed-article:15612023 | pubmed:meshHeading | pubmed-meshheading:15612023... | lld:pubmed |
| pubmed-article:15612023 | pubmed:meshHeading | pubmed-meshheading:15612023... | lld:pubmed |
| pubmed-article:15612023 | pubmed:meshHeading | pubmed-meshheading:15612023... | lld:pubmed |
| pubmed-article:15612023 | pubmed:year | 2005 | lld:pubmed |
| pubmed-article:15612023 | pubmed:articleTitle | Phase II study of irinotecan (CPT-11) as salvage therapy for advanced nasopharyngeal carcinoma. | lld:pubmed |
| pubmed-article:15612023 | pubmed:affiliation | Department of Medical Oncology, National Cancer Center, Singapore. | lld:pubmed |
| pubmed-article:15612023 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:15612023 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:15612023 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:15612023 | pubmed:publicationType | Clinical Trial, Phase II | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:15612023 | lld:pubmed |
